3D Net Perfusion
Biotronics3D has worked with the ICR to develop and launch new software which could significantly improve the accuracy of Magnetic Resonance Imaging (MRI) analysis. Called 3D Net Perfusion, the system extracts data from images of tumours and transforms it into usable information.
3D Net Perfusion provides clinicians and scientists with a new way of visualising data and extracting measurable information about blood supply to tumours, an important factor in tumour growth. This information is extremely valuable when studying a patient’s response to a drug, and can also be used to aid diagnosis and disease management.
The software is a result of pioneering trials at the ICR, led by Professor Martin Leach, David Collins and James d’Arcy, and is currently in use in 20 different academic research centres worldwide. “Following our successful pilot trials, we are delighted to be working with Biotronics3D to make these important developments available to clinicians and scientists at other centres working on improving cancer diagnosis and treatment." says Professor Martin Leach, Co-Director of the Cancer Research UK Clinical Magnetic Resonance Research Group.
Paul Carnochan, Senior Business Development Manager at the ICR, believes the partnership could have broader implications: “London has an abundance of research capabilities and commercial expertise in the field of medical imaging, and we believe that collaborations like this one can be the key to raising London’s profile as a major biotech hub.”
The continued work between The Cancer Research UK and Engineering and Physical Sciences Research Council (EPSRC) Cancer Imaging Centre at the ICR and Royal Marsden, and Biotronics3D, aims to further enhance the software and enable the technology to reach a much larger market.
Harry Hatzakis, CEO of Biotronics3D, comments: “Innovation carries risks, and in fast moving markets such as global diagnostics, it is important to leverage skills that exist outside of a company through partnerships, such as ours with the ICR.”
